Signed a licensing agreement with Braveheart Bio for the HRS-1893 project
September 5, 2025
Source: drugdu
104
September 5, Hengrui Medicine announced in the morning that it had reached an agreement with BraveheartBio, Inc. (hereinafter referred to as "Braveheart Bio") of the United States to have independent intellectual property rights .Category 1 innovative drugsHengrui is licensed the HRS-1893 (HRS-1893) program to Braveheart Bio for a fee. Braveheart Bio will pay Hengrui an upfront payment of US$65 million (consisting of US$32.5 million in cash and an equivalent of US$32.5 million in Braveheart Bio equity) and US$10 million in near-term milestone payments upon completion of technology transfer, for a total of US$75 million. Hengrui is eligible to receive milestone payments related to clinical development and sales, up to US$1.013 billion.
https://finance.eastmoney.com/a/202509053505416531.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
